{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:54Z","timestamp":1791331254642,"version":"4.3.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10147-018-1368-2","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T06:00:01Z","timestamp":1542002401000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)"],"prefix":"10.1007","volume":"24","author":[{"given":"Shin","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Komukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"1368_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"1368_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M et al (2012) Chronic myeloid leukemia stem cells are not dependent on BCR-ABL kinase activity for their survival. Blood 119:1501\u20131510","journal-title":"Blood"},{"key":"1368_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"1368_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D et al (2017) Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298\u2013305","journal-title":"J Clin Oncol"},{"key":"1368_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment\u2013free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG\u2013STIM213 study. Int J Hematol 107:185\u2013193","journal-title":"Int J Hematol"},{"key":"1368_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"1368_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424\u2013430","journal-title":"J Clin Oncol"},{"key":"1368_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, Le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90:910\u2013914","journal-title":"Am J Hematol"},{"key":"1368_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757","journal-title":"Lancet Oncol"},{"key":"1368_CR10","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528\u2013e535","journal-title":"Lancet Haematol"},{"key":"1368_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW et al (2018) Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase. Results from a single-group, phase 2, open-label study. Ann Intern Med 168:461\u2013470","journal-title":"Ann Intern Med"},{"key":"1368_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K et al (2012) Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17:584\u2013589","journal-title":"Int J Clin Oncol"},{"key":"1368_CR13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34:2333\u20132340","journal-title":"J Clin Oncol"},{"key":"1368_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054","journal-title":"Leukemia"},{"key":"1368_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17\u201323","journal-title":"Blood"},{"key":"1368_CR16","unstructured":"NCCN Clinical practice guidelines in oncology. Chronic Myeloid Leukemia Version 4. 2018-January 24, 2018"},{"issue":"suppl_4","key":"1368_CR17","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G et al (2017) Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv41\u2013i51","journal-title":"Ann Oncol"},{"key":"1368_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY et al (2016) Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101:717\u2013723","journal-title":"Haematologica"},{"key":"1368_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H et al (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108\u20131116","journal-title":"Leukemia"},{"key":"1368_CR20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A et al (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638\u20131647","journal-title":"Leukemia"},{"key":"1368_CR21","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818\u20133824","journal-title":"Blood"},{"key":"1368_CR22","doi-asserted-by":"publisher","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E et al (2011) Chronic myeloid leukemia patients in prolonged remission following interferon-\u03b1 monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 6:e23022","journal-title":"PLoS One"},{"key":"1368_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H et al (2009) Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135\u2013139","journal-title":"Haematologica"},{"key":"1368_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398\u20131405","journal-title":"Leukemia"},{"key":"1368_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376:917\u2013927","journal-title":"N Engl J Med"},{"key":"1368_CR26","volume-title":"CML\/MPN (2018) JSH Practical guidelines for hematological malignancies","year":"2018","unstructured":"Shimoda K, Kawaguchi T, Kizaki M (eds) (2018) CML\/MPN (2018) JSH Practical guidelines for hematological malignancies. Tokyo: Kanehara Shuppan, Co. Ltd."}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1368-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:25:31Z","timestamp":1573518331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1368-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1368-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. Fujisawa has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding form Pfizer and Novartis. K. Usuki has received honoraria from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical and research funding from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Astellas Pharma, Otsuka, Kyowa Kirin, Glaxo Smithkline K.K, Sanofi K.K, Shire Japan, Symbio Pharmaceuticals Limited, Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K,K. Y. Kanda has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding from Pfizer and Otsuka Pharmaceuticals. T. Kumagai has held an advisory role for Novartis and has received honoraria from Bristol-Myers Squibb, Pfizer, and Otsuka. K. Inokuchi has held an advisory role for Novartis and Otsuka Pharmaceutical and has received honoraria from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer and research funding from Bristol-Myers Squibb. T. Kondo has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Celgene and research funding Bristol-Myers Squibb. C. Yoshida has received honoraria from Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceuticals. Y. Maeda has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Celgene and research funding from Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceuticals. K. Kojima has held an advisory role for Janssen Asia Pacific (Singapore) and has received research funding from Janssen Global (USA), and PTC Therapeutics (USA). S. Morita has received honoraria from Bristol-Myers Squibb, and Pfizer. J. Sakamoto has held an advisory role for Takeda and has received honoraria from Chugai, Nihon Kayaku, and Tsumura. S. Kimura has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Ohara pharmaceutical. All remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}